NCT00826033

Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer

Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: —
• Sponsor: Gunma University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

L-\[3-18F\]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The investigators evaluated the value of 18F-FMT PET for the assessment of therapy response in patients with lung cancer as compared with that of 2-\[18F\]-fluoro-2-deoxy-D-glucose (18F-FDG) PET. The patients with lung cancer underwent PET studies with 18F-FDG and 18F-FMT before and after radio-/chemotherapy. The investigators used the ratio of the SUVmax of the mediastinal (N2) lymph node to the SUVmax of the primary tumor (N/P ratio ). All patients were divided into two groups of N/P ratio\<1 and N/P ratio≥1, and the survival time was estimated by Kaplan-Meier method.

Conditions

• Non-Small Cell Lung Cancer

Timeline

• First posted: 2009-01-21
• Last updated: 2009-01-21

Locations

1 site across 1 country: Japan